Ramtin Agah Purchases 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) Stock

RenovoRx, Inc. (NASDAQ:RNXT) insider Ramtin Agah acquired 15,000 shares of the stock in a transaction dated Tuesday, April 15th. The shares were bought at an average cost of $0.90 per share, with a total value of $13,500.00. Following the transaction, the insider now directly owns 1,113,460 shares of the company’s stock, valued at $1,002,114. This represents a 1.37 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ramtin Agah also recently made the following trade(s):

• On Friday, April 11th, Ramtin Agah bought 20,000 shares of RenovoRx stock. The stock was bought at an average cost of $0.80 per share, with a total value of $16,000.00.
• On Tuesday, April 8th, Ramtin Agah purchased 26,000 shares of RenovoRx stock. The stock was purchased at an average cost of $0.84 per share, for a total transaction of $21,840.00.

RenovoRx Stock Down 1.0 %

Shares of RNXT stock opened at $1.02 on Friday. RenovoRx, Inc. has a 12 month low of $0.75 and a 12 month high of $1.69. The company’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.13. The firm has a market cap of $37.28 million, a PE ratio of -1.79 and a beta of 1.12.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.17 million. On average, equities analysts predict that RenovoRx, Inc. will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new stake in shares of RenovoRx during the 4th quarter worth approximately $49,000. Renaissance Technologies LLC bought a new position in shares of RenovoRx in the fourth quarter valued at $84,000. Finally, Geode Capital Management LLC increased its holdings in RenovoRx by 61.9% during the third quarter. Geode Capital Management LLC now owns 232,937 shares of the company’s stock worth $247,000 after buying an additional 89,018 shares during the last quarter. 3.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of RenovoRx in a report on Friday, April 4th.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.